Treatment of gastroesophageal reflux disease in adults: An individualized approach

Digestive Diseases

Volumn 22, Issue 2, 2004, Pages 148-160

  Galmiche, Jean Paul ^a   Stephenson, Kate ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Gastroesophageal reflux disease; Long term management; Maintenance therapy; On demand therapy; Proton pump inhibitor

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ACID; CISAPRIDE; DOMPERIDONE; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SUCRALFATE;

ABDOMINAL SURGERY; ADULT; BARRETT ESOPHAGUS; CANCER RISK; CLINICAL TRIAL; CONSENSUS; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENDOSCOPY; ESOPHAGITIS; ESOPHAGUS DISEASE; ESOPHAGUS STRICTURE; EXPOSURE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HEALTH CARE NEED; HEART DISEASE; HUMAN; HYPERSENSITIVITY; LONG TERM CARE; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; MEDICAL ASSESSMENT; PATHOPHYSIOLOGY; PATIENT; PATIENT INFORMATION; PHYSICIAN; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; STOMACH ACID; SURGICAL TECHNIQUE; SYMPTOM; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTI-ULCER AGENTS; CHRONIC DISEASE; ENZYME INHIBITORS; GASTROESOPHAGEAL REFLUX; HUMANS; PROTON PUMPS; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX;

EID: 4644342208     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080314     Document Type: Review

References (100)

1. Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ: Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted Country, Minnesota. Gastroenterology 1997;112:1448-1456.
2. Dent J, Armstrong D, Delaney B, Moayyedi P, Talley NJ, Vakil N: Symptom evaluation in reflux disease: Workshop background, processes, terminology, recommendations, and discussion outputs. Gut 2004;53(suppl IV):iv1-iv24.
3. Dent J, Brun J, Fendrick M, Fennerty MB, Janssens J, Kahrilas PJ, Lauritsen K, Reynolds JC, Shaw M, Talley NF, the Genval Workshop Group: An evidence-based appraisal of reflux disease management - The Genval Workshop Report. Gut 1999;44(suppl 2):S1-S16.
4. Cadiot G, Bruhat A, Rigaud D, Coste T, Vuagnat A, Benyedder T, Vallot T, Le Guludec D, Mignon M: Multivariate analysis of pathophysiological factors in reflux oesophagitis. Gut 1997;40:167-174.
5. Galmiche JP, Barthélémy P, Hamelin B: Treating the symptoms of gastro-oesophageal reflux disease: A double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997;11:765-773.
6. Jones RH, Hungin APS, Philips J, Mills JG: Gastro-oesophageal reflux disease in primary care in Europe: Clinical presentation and endoscopic findings. Eur J Gen Pract 1995;1:149-154.
7. Kulig M, Leodolter A, Vieth M, Schulte S, Jaspersen D, Labenz J, Lind T, Meyer-Sabellek W, Malfertheiner P, Stolde M, Willich SN: Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease - An analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003;18:767-776.
8. Revicki DA, Wood M, Maton PN, Sorensen S: The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998;104:252-258.
9. Gold BD: Epidemiology and management of gastro-oesophageal reflux in children. Aliment Pharmacol Ther 2004;19:22-27.
10. Pandolfino JE, Kahrilas PJ: Smoking and gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2000;12:837-842.
11. Richter JE, Kovacs TOG, Greski-Rose PA, Huangs B, Eisher R: Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 1999;13:795-804.
12. Miner P, Orr W, Filippone J, Jokubaitis L, Sloan S: Rabeprazole in nonerosive gastroesophageal reflux disease: A randomized placebo-controlled trial. Am J Gastroenterol 2002;97:1332-1339.
13. Bate CM, Griffin SM, Keeling PWN, Axon ATR, Dronfield MW, Chapman RWG, O'Donoghue D, Calam J, Crowe J, Mountford RA, Watts DA, Taylor MD, Richardson PDI: Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996;10:547-555.
14. Bate CM, Green JR, Axon AT, Murray FE, Tildesley G, Emmas CE, Taylor MD: Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. Aliment Pharmacol Ther 1997;11:755-763.
15. Hatlebakk JG, Hyggen A, Madsen PH, Walle PO, Schulz T, Mowinckel P, Bernklev T, Berstad A: Heartburn treatment in primary care: Randomised, double blind study for 8 weeks. BMJ 1999;319:550-553.
16. Lind T, Havelund T, Carlsson R, Anker-Hanssen O, Glise H, Hernqvist H, Junghard O, Lauritsen K, Lundell L, Pedersen SA, Stuberöd A: Heartburn without oesophagitis: Efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997;32:974-979.
17. Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML: Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997;32:965-973.
18. Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, Haug K, de Groot G, van Oudvorst A, Dalväg ZA, Junghard O, Wiklund I: Gastro-oesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998;10:119-124.
19. Van Pinxteren B, Numans ME, Bonis PA, Lau J: Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2001;4:CD002095.
20. Richter JE, Campbell DR, Kahrilas PJ, Huang B, Fludas C: Lansoprazole compared with ranitidine for the treatment of non-erosive gastroesophageal reflux disease. Arch Intern Med 2000;160:1803-1809.
21. Scarpignato C, Galmiche JP: The role of H2-receptor antagonists in the era of proton pump inhibitors; in Lundell L (ed): Guidelines for Management of Symptomatic Gastro-Oesophageal Reflux Disease. London, Science Press, 1998, pp 55-66.
22. Bruley des Varannes S, Duquesnoy C, Mamet JP, Slama A, Galmiche JP, Scarpignato C: Effects of tablet and effervescent formulations of ranitidine 75 mg and cimetidine 200 mg on gastric acidity and esophageal acid exposure in healthy humans. Aliment Pharmacol Ther 1998;12:1155-1161.
23. Earnest D, Robinson M, Rodriguez-Stanley S, Ciociola AA, Jaffe P, Silvers MT, Kleoudis CS, Murdock RH: Managing heartburn at the 'base' of the GERD 'iceberg': Effervescent ranitidine 150 mg b.d. provides faster and better heartburn relief than antacids. Aliment Pharmacol Ther 2000;14:911-918.
24. Peterson WL: Improving the Management of GERD: Evidence-Based Therapeutic Strategies. Consensus Opinion in Gastroenterology. Richmond, American Gastroenterological Association, 2002.
25. Galmiche JP, Shi G, Simon B, Casset-Semanaz F, Slama A: On-demand treatment of gastrooesophageal reflux symptoms: A study comparing ranitidine 75 mg with placebo and cimetidine 200 mg. Aliment Pharmacol Ther 1998;12:909-917.
26. French-Belgian Consensus Conference on Adult Gastro-Oesophageal Reflux Disease 'Diagnosis and Treatment': Report of a meeting held in Paris, France, on 21-22 January 1999. The Jury of the consensus conference. Eur J Gastroenterol Hepatol 2000;12:129-137.
27. Wallace MB, Durkalski VL, Vaughan J, Palesch YY, Libby ED, Jowell PS, Nickl NJ, Schutz SM, Leung JW, Cotton PB: Age and alarm symptoms do not predict endoscopic findings among patients with dyspepsia: A multicentre database study. Gut 2001;49:29-34.
28. Kearney DJ, Crump C, Maynard C, Boyko EJ: A case-control study of endoscopy and mortality from adenocarcinoma of the esophagus or gastric cardia in persons with GERD. Gastrointest Endosc 2003;57:823-829.
29. Panter SJ, O'Flanagan H, Bramble MG, Hungin PS: Empirical use of antisecretory drug therapy delays diagnosis of upper gastrointestinal adenocarcinoma but does not effect outcome. Aliment Pharmacol Ther 2004;19:981-988.
30. Tytgat GNJ: Review article: Management of mild and severe gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003;17(suppl 2):52-56.
31. Inadomi JM, Jamal R, Murata GH, Hoffman RM, Lavezo LA, Vigil JM: Step-down management of gastroesophageal reflux disease. Gastroenterology 2001;121:1095-1100.
32. Katz PO, Castell DO, Levine D: Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 2003;18:875-882.
33. Chey W, Huang B, Jackson RL: Lansoprazole and esomeprazole in symptomatic GERD. Drug Invest 2003;23:69-84.
34. Tack J, Fass R: Review article: Approaches to endoscopic-negative reflux disease: Part of the GERD spectrum or a unique acid-related disorder? Aliment Pharmacol Ther 2004;19 (suppl 1):28-34.
35. Cicala M, Emerenziani S, Caviglia R, Guarino MPL, Vavassori P, Ribolsi M, Carotti S, Petitti T, Pallone F: Intra-oesophageal distribution and perception of acid reflux in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003;18:605-613.
36. Gardner JD, Gallo-Torres H, Sloan S, Robinson M, Miner PF: The basis for the decreased response to proton pump inhibitors in gastrooesophageal reflux disease patients without erosive oesophagitis. Aliment Pharmacol Ther 2003;18:891-905.
37. Shi G, Bruley des Varannes S, Scarpignato C, Le Rhun M, Galmiche JP: Reflux-related symptoms in patients with normal oesophageal exposure to acid. Gut 1995;37:457-464.
38. Watson RGP, Tham TCK, Johnston BT, McDougall NI: Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux - The 'sensitive oesophagus'. Gut 1997;40:587-590.
39. Sifrim D, Holloway R, Silny J, Xin Z, Tack J, Lerut A, et al: Acid, non-acid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology 2001;120:1588-1598.
40. Vela MF, Tutuian R, Katz PO, Castell DO: Baclofen decreases acid and non-acid postprandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003;17:243-251.
41. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997;112:1798-1810.
42. Farley A, Wruble LD, Humphries TJ: Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: A double-blind, randomized clinical trial. Am J Gastroenterol 2000;95:1894-1899.
43. Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW, Whipple J, D'Amico D, Hamelin B, Joelson B, for the Esomeprazole Study Investigators. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomised controlled trial. Aliment Pharmacol Ther 2000;14:1249-1258.
44. Howden CW, Ballard ED II, Robieson W: Evidence for therapeutic equivalence of lansoprazole 30 mg and esomeprazole 40 mg in the treatment of erosive oesophagitis. Clin Drug Invest 2002;22:99-109.
45. Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L: Onset of symptom relief with rabeprazole: A community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther 2002;16:445-454.
46. Richter JE, Kahrilas PJ, Sontag SJ, Kovacs TOG, Huang B, Pencyla JF: Comparing lansoprazole and omeprazole in onset of heartburn relief: Results of a randomized controlled trial in erosive esophagitis patients. Am J Gastroenterol 2001;96:3089-3098.
47. Vakil N, Fennerty MB: Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. Aliment Pharmacol Ther 2003;18:559-568.
48. Scholten T, Gatz G, Hole U: Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERDrelated symptoms. Aliment Pharmacol Ther 2003;18:587-594.
49. Martinek J, Pantoflickova D, Hucl T, Benes M, Dorta G, Lukas M, Spicak J: Absence of nocturnal acid breakthrough in Helicobacter pylori-positive subjects treated with twice-daily omeprazole. Eur J Gastroenterol Hepatol 2004;16:445-450.
50. McColl KEL: Helicobacter pylori infection and long-term proton pump inhibitor therapy. Gut 2004;53:5-7.
51. Hammer J, Schmidt B: Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough. Aliment Pharmacol Ther 2004;19:1105-1110.
52. Pehlivanov ND, Olyaee M, Sarosief I, McCallum RW: Comparison of morning and evening administration of rabeprazole for gastrooesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: A double-blind, cross-over study. Aliment Pharmacol Ther 2003;18:883-890.
53. Peghini PL, Katz PO, Castell DO: Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects. Gastroenterology 1998;115:1335-1339.
54. Fackler WK, Ours TM, Vaezi M, Richter JE: Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002;122:625-632.
55. Koek GH, Sifrim D, Lerut T, Janssens J, Tack J: Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastroesophageal reflux refractory to proton pump inhibitors. Gut 2003;52:1397-1401.
56. Vakil N: New pharmacological agents for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004;19:1041-1049.
57. Hirsch DP, Tytgat GNJ, Boeckxstaens GE: Transient lower esophageal sphincter relaxations - A pharmacological target for gastroesophageal reflux disease? Aliment Pharmacol Ther 2002;16:17-26.
58. Galmiche JP: New drug developments in gastroesophageal reflux disease; in Farthing MJG, Malfertheiner P (eds): Update Gastroenterology 2002 - Basic Mechanisms of Digestive Disease: The Rationale for Clinical Management and Prevention. Paris, Libbey Eurotext, 2002, pp 1-11.
59. Ciccaglione AF, Marzio: Effect of acute and chronic administration of the GABAB agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastrooesophageal reflux disease. Gut 2003;52:464-470.
60. Laugier R, Devière J, Costamagna G, Letard JC, Tringali A, Grandval P: Biliary reflux in gastrectomized patients: Treatment by ethylene-vinyl-alcohol polymer (Enterix) injection (abstract). Gastroenterology 2004;126:M1433.
61. Floch NR: Surgical therapy of atypical symptoms of GERD. Patient selection and preoperative evaluation. J Clin Gastroenterol 2000;30:S45-S47.
62. Marks RD, Richter JE: Peptic strictures of the esophagus. Am J Gastroenterol 1993;88:1160-1173.
63. Smith PM, Kerr GD, Cockel R, Ross BA, Bate CM, Brown P, Dronfield MW, Green JR, Hislop WS, Theodossi A, et al: A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Gastroenterology 1994;107:1312-1318.
64. Tutuian R, Katz PO, Castell DO: Nocturnal acid breakthrough: pH, drugs and bugs. Eur J Gastroenterol Hepatol 2004;16:441-443.
65. Peters FT, Ganesh S, Kuipers EJ, Sluiter WJ, Klinkenberg-Knol EC, Lamers CB, Kleibeuker JH: Endoscopic regression of Barrett's oesophagus during omeprazole treatment: A randomised double blind study. Gut 1999;45:489-494.
66. Arts J, Tack J, Galmiche JP: Endoscopic antireflux procedures. Gut 2004;53:1207-1214.
67. Freston JW, Triadafilopoulos G: Review article: Approaches to the long-term management of adults with GERD - Proton pump inhibitor therapy, laparoscopic fundoplication or endoscopic therapy? Aliment Pharmacol Ther 2004;19:35-42.
68. Bardhan KD, Müller-Lissner S, Bigard MA, Bianchi Porro G, Ponce J, Hosi J, Scott JH, Weir DG, Gillon KRW, Peacock RA: Symptomatic gastro-oesophageal reflux disease: Double blind controlled study of intermittent treatment with omeprazole or ranitidine. BMJ 1999;318:502-507.
69. Carlsson R, Galmiche JP, Dent J, Lundell L, Frison L: Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: A meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997;11:473-482.
70. Lauritsen K, Devière J, Bigard MA, Bayerdorffers E, Mozsik G, Murray F, Krisjandottir S, Savarino V, Vetvik K, De Freitas D, Orive V, Rodrigo L: Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis. Metropole study results. Aliment Pharmacol Ther 2003;17:333-341.
71. Talley NF, Venables TL, Green JBR, Armstrong D, O'Kane KPJ, Giaffer M, Bardhan KD, Carlsson R, Chen S, Hasselgren G: Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative GERD: A placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002;14:857-863.
72. Thjodleifsson B, Beker JA, Dekkers C, Bjaaland T, Finnegan V, Humphries TJ: Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease. A double-blind, multicentre, European trial. Dig Dis Sci 2000;45:845-853.
73. Venables TL, Newland RD, Patel AC, Hole J, Copeman MB, Turbitt ML: Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice. Scand J Gastroenterol 1997;32:627-632.
74. Bate CM, Booth SN, Crowe JP, Mountford RA, Keeling PWN, Hepworth-Jones B, Taylor MD, Richardson PDI: Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Gut 1995;36:492-498.
75. Birbara C, Breiter J, Perdomo C, Hahne W: Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2000;12:889-897.
76. Caos A, Moskovitz M, Dayal Y, Perdomo C, Niecestro R, Barth J: Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Am J Gastroenterol Hepatol 2000;95:3081-3088.
77. Johnson DA, Benjamin SB, Vakil NB, Goldstein JL, Lamet M, Whipple J, D'Amico D, Hamelin B: Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: A randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001;96:27-34.
78. You JHS, Lee ACM, Wong SCY, Chan FKL: Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: A cost-effectiveness analysis. Aliment Pharmacol Ther 2003;17:785-792.
79. Thjodleifsson B, Rindi G, Fiocca R, Humphries TJ, Morocutti A, Miller N, Bardhan KD: A randomised, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. Aliment Pharmacol Ther 2003;17:343-351.
80. Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, Lloyd D, Havu N, Frame MH, Roman J, Walan A, Group LT: Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000;118:661-669.
81. Kuipers EJ, Meuwissen SGM: The efficacy and safety of long-term omeprazole treatment for gastroesophageal reflux disease. Gastroenterology 2000;118:795-801.
82. Johnsson F, Moum B, Vilien M, Grove O, Simren M, Thoring M: On-demand treatment in patients with oesophagitis and reflux symptoms: Comparison of lansoprazole and omeprazole. Scand J Gastroenterol 2002;37:642-647.
83. Lind T, Havelund T, Lundell L, Glise H, Lauritsen K, Pedersen SA, Anker-Hansen O, Stubberod A, Eriksson G, Carlsson R, Junghards O: On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - A placebo-controlled randomized trial. Aliment Pharmacol Ther 1999;13:907-914.
84. Talley NJ, Lauritsen K, Tunturi-Hihnala H, Lind T, Moum B, Bang C, Schulz T, Omland TM, Delle M, Junghard O: Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: A controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol Ther 2001;15:347-354.
85. Meineche-Schmidt V, Hauschildt Juhl H, Ostergaard JE, Luckow A, Hvenegaard A: Costs and efficacy of three different esomeprazole treatment strategies for long-term management of gastro-oesophageal reflux symptoms in primary care. Aliment Pharmacol Ther 2004;19:907-915.
86. Bateman DN, Colin-Jones D, Hartz S, Langman M, Logan RF, Mant J, Murphy M, Paterson KR, Rowsell R, Thomas S, Vessey M: Mortality study of 18,000 patients with omeprazole. Gut 2003;52:942-946.
87. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, Snel P, Goldfain D, Kolkman JJ, Festen HPM, Dent J, Zeitoun P, Havu N, Lamm M, Walan A: Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: Results of a randomised controlled trial. Gut 2004;53:12-20.
88. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon ATR: Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001;121:1120-1126.
89. Malfertheiner P: Helicobacter pylori eradication does not exacerbate gastro-oesophageal reflux disease. Gut 2004;53:312-313.
90. Schwizer W, Thumshirrn M, Dent J, Guldenschuh I, Menne D, Cathomas G, Fried M: Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: A randomised controlled trial. Lancet 2001;357:1738-1742.
91. Wu JCY, Chan FKL, Ching JYL, Leung WK, Leong R, Chung SCS, Sung JJY: Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: A double blind, placebo, controlled, randomised trial. Gut 2004;53:174-179.
92. Galmiche JP, Zerbib F: Debate: Laparoscopic fundoplication is the treatment of choice for gastro-oesophageal reflux disease. Protagonist view. Gut 2002;51:472-474.
93. Spechler SJ: Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. N Engl J Med 1992;326:786-792.
94. Spechler SJ, Lee E, Ahnen D, et al: Long-term outcome of medical and surgical therapies of gastroesophageal reflux disease: Follow-up of a randomized controlled trial. JAMA 2001;285:2331-2338.
95. Lundell L, Miettinen P, Myrvold HE, et al: Long-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: Results of a prospective, randomized clinical trial. The Nordic GORD Study Group. Eur J Gastroenterol Hepatol 2000;12:879-887.
96. Lundell L, Miettinen P, Myrvold HE, et al: Continued (5-year) follow-up of a randomised clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 2001;192:172-179.
97. Fenton P, Terry ML, Galloway KD, Smith C, Hunter JG, Waring P: Is there a role for laparoscopic fundoplication in patients with nonerosive reflux disease (NERD)? Gastroenterology 2000;118(suppl 2):A481.
98. Thibault R, Sacher-Huvelin S, Gournay J, Bruley des Varannes S, Letessier E, Galmiche JP: Chirurgie anti-reflux et reflux gastrooesophagien sans oesophagite: étude cas-témoins (abstract). Gastroenterol Clin Biol 2004;28:A95.
99. Farrell TM, Richardson WS, Trus TL, Smith CD, Hunter JG: Response of atypical symptoms of gastro-oesophageal reflux to antireflux surgery. Br J Surg 2001;88:1649-1652.
100. Corley DA, Katz P, Wo JM, Stefan A, Patti M, Rothstein R, Edmundowicz S, Kline M, Mason R, Wolfe M: Improvement of gastroesophageal reflux symptoms after radiofrequency energy: A randomized, sham-controlled trial. Gastroenterology 2003;125:668-676.